A 45-year-old man initially deemed to have depression was later diagnosed with parkinsonian syndrome following a skin biopsy that detected alpha-synuclein, a protein that forms toxic clumps in the brains of people with Parkinson’s disease, according to a case study from researchers in Miami. After receiving a combination of carbidopa…
Early data on recruitment and enrollment from Photopharmics’ Phase 3 clinical trial of its light-based, at-home therapy device for Parkinson’s disease — a novel treatment called Celeste — highlight both the interest in, and feasibility of, fully remote studies done in a patient’s home, according to the company. Such home-based, decentralized…
The Michael J. Fox Foundation for Parkinson’s Research (MJFF) recognized a Texas scientist for his contributions to Parkinson’s research and his commitment to mentoring the next generation of Parkinson’s scientists. Claudio Soto, PhD, a professor of neurology and director of the George and Cynthia Mitchell Center for Alzheimer’s…
An investigational treatment for Parkinson’s disease known as GT-02287 safely led to a roughly 53% increase in GCase enzyme activity, as measured in dried blood spots from treated healthy adults relative to those given a placebo in a Phase 1 clinical trial, its developer, Gain Therapeutics, reported. This…
People who received five or more courses of penicillin antibiotic treatment in the five years before a Parkinson’s diagnosis had an approximately 15% lower risk of developing the disease than those who took no antibiotics, according to a Rutgers Health study. Conversely, treatment with two or more courses of…
A process known as SUMOylation plays an important role in the so-called waking up of neural stem cells, a type of cell in the brain that can self-renew and mature into nerve cells, according to a new study in fruit flies by an international team of researchers led by Duke-NUS…
Allyx Therapeutics has received a $3.3 million grant from the National Institutes of Health (NIH) to initiate a Phase 1 clinical trial to evaluate the interaction of its investigational oral therapy ALX-001 with other medications and assess how the drug can affect patients who take multiple medications. The grant,…
A novel technology based on gene therapy enables precise and noninvasive control of specific brain circuits using magnetic fields, allowing select nerve cells to be turned on or off, a study reports. This magnetogenetics technology — a result of collaboration between Weill Cornell Medicine at Cornell University, The Rockefeller University,…
New U.S. Department of Defense-funded research at Binghamton University in New York is investigating the underlying causes of neuropsychiatric symptoms — those that result from medical conditions involving both neurologic and psychiatric components — in people with Parkinson’s disease. The four-year grant, totaling $3 million, is shared between Binghamton,…
The Centre for Medicines Discovery at the University of Oxford and BPGbio, an artificial intelligence (AI)-focused biopharmaceutical company, established a five-year research collaboration that aims to advance new technologies for treatments for people with brain diseases like Parkinson’s who have limited options. Together the partners will validate and…
Get regular updates to your inbox.